David E I Pyott

CIK 1051578 · Chairman of the Board and CEO · last filed 2026-11-12

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$44.18M
Companies
7
Total Filings
133
Lifetime Open-Market Net
-$267.52M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

AGN price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE
CAMBRIDGE, MA 02142
Related Filers
ALNYLAM PHARMACEUTICALS, INC. — 22 joint filings, latest 2026-06-03
BIOMARIN PHARMACEUTICAL INC — 12 joint filings, latest 2024-05-23
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALNY Director 33,262 $147.82 $4.92M -$9.50M 19 2026-11-12
TARS Director 10,958 $77.67 $851.1K $0 4 2026-09-17
PLRX Director — $0.62 — $0 7 2025-06-09
BMRN Director 49,750 $61.42 $3.06M $1.00M 11 2024-05-23
AVY Director 18,684 $183.14 $3.42M -$1.33M 50 2020-04-24
ALLERGAN INC (AGN) Delisted Chairman of the Board and CEO 399,832 — — -$250.59M 25 2015-02-24
EW Director 307,440 $103.88 $31.94M -$7.10M 13 2013-05-17

Holdings By Holder

Who holds the shares on record: the insider directly, and each trust, LLC, partnership or family member reported as an indirect holder on the latest Form 4 that lists them. Holder names come from the filing's footnotes. Rows under No longer reported appeared on earlier filings but not the latest one, usually because the holder was emptied or folded into another; they are not counted in the total.
Symbol Holder Shares Share of Total Reported
ALNY Direct 5,362 16.1% 2026-11-12
by Trust 27,900 83.9% 2026-11-12
Total 33,262
TARS Direct 1,383 12.6% 2026-04-28
By the David E.I. Pyott Trust 9,575 87.4% 2026-09-17
Total 10,958
AGN Direct 165,659 41.4% 2015-02-24
By Living Trust 229,096 57.3% 2015-02-24
By Esop Trust 2,896 0.7% 2015-02-24
By 401(k) Trust 2,180 0.5% 2015-02-24
Total 399,832

10b5-1 Trading Plans

3 plans
Plans this person adopted or ended, as the company reported them in its 10-Q or 10-K. A Rule 10b5-1 plan sets trades in advance; a director's or officer's plan can't sell until a cooling-off period ends, 90 to 120 days after adoption. Sold so far adds up the open-market sales filed on Form 4 under a plan since it was adopted, and the percentage is of the shares the plan allows.
Company Adopted Sales Can Start Ends Plan Allows Sold So Far Status Link
ALNY
member of our board of directors
Nov 12, 2025 Feb 16, 2026 Oct 14, 2026 7,610 shares 3,830 (50%)
last filed Jun 3, 2026
Ended 10-K
ALNY
Director
Sep 5, 2024 Dec 4, 2024 Dec 17, 2025 7,440 shares 7,440 (100%)
last filed Mar 25, 2025
Ended 10-Q
ALNY
Director
Aug 11, 2023 Nov 9, 2023 Aug 10, 2024 32,450 shares 32,450 (100%)
last filed Jun 26, 2024
Ended 10-Q
Sales can start: the later of 90 days after adoption and two business days after the report for the quarter it was adopted in, capped at 120 days. Ends: the end date the company gave, or adoption plus the plan's stated length; a plan can also end sooner once its shares are sold. Ended early means the company reported the plan terminated before that date. Sold so far is left blank while a plan is cooling off, and when a stock split falls inside the plan the percentage is left out because the limit is in pre-split shares.

Recent Filings · Page 12 of 14

133 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2009-05-12 EW Grant (A) +3,150 $0 EDGAR
2009-04-01 AVY Grant (A) — $0 EDGAR
2009-02-27 AVY Grant (A) — $0 EDGAR
2009-02-24 ALLERGAN INC (AGN) Delisted Grant (A) — $0 EDGAR
2008-12-18 AVY Grant (A) — $0 EDGAR
2008-11-06 ALLERGAN INC (AGN) Delisted Buy (P) +25,000 $958.7K EDGAR
2008-10-15 ALLERGAN INC (AGN) Delisted Mixed −8,675 -$366.3K EDGAR
2008-10-01 AVY Grant (A) — $0 EDGAR
2008-07-01 AVY Grant (A) +750 $0 EDGAR
2008-05-13 EW Grant (A) +3,658 $0 EDGAR
Showing 111–120 of 133
Page 12 of 14
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).